When was Adcendo founded?

Adcendo was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Adcendo located?

Adcendo is headquartered in Frederiksberg, Denmark.

Which legal entities is Adcendo associated with?

Adcendo is associated with ADCendo ApS.

How many employees does Adcendo have?

As of Mar 31, 2026, the latest employee count at Adcendo is 59.

Is Adcendo a funded company?

Adcendo is a funded company, having raised a total of $323M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 16, 2017.

When was the latest funding round of Adcendo?

Adcendo's latest funding was a $***** Series C round on Apr 14, 2026, with participation from 17 investors.

Where does Adcendo rank among its competitors?

Adcendo ranks 253rd amongst 3224 active competitors, of which 1107 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Adcendo?

Adcendo's top competitors include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Among them, Adcendo secured the most recent funding round in April, 2026.

Adcendo - 2026 Company Profile, Team, Funding, Competitors & Financials

Adcendo is a series C company based in Frederiksberg (Denmark), founded in 2017 by Lars Henning Engelholm and Niels Behrendt. It operates as a Developer of antibody-drug conjugates for the treatment of cancer. Adcendo has raised $323M in funding from investors like Ysios Capital, Pontifax and Dawn Biopharma, with a current valuation of $*****. The company has 3224 active competitors, including 1107 funded and 768 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and Sana Biotechnology.

Company Details

Developer of antibody-drug conjugates for the treatment of cancer. The company's drug is developed to target specialized endocytic receptors that are uPARAP and endo180. It allows targeted therapy in cancer, including soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

Website: adcendo.com
Email ID: *****@adcendo.com

Key Metrics

Founded Year

2017

Location

Frederiksberg, Denmark

Stage

Series C

Total Funding

$323M in 6 rounds

Latest Funding Round

Series C, Apr 14, 2026, $*****

Investors

Ysios Capital & 14 more

Ranked

253^rd among 3224 active competitors

Employee Count

59 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3038 more

View Adcendo's full profile

Adcendo is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ADCendo ApS CIN: 38780093 , Denmark, Active	Jun 30, 2017	-	40 (As on Nov 30, 2024)

Adcendo has raised a total funding of $323M over 6 rounds. Its first funding round was on Nov 16, 2017. Its latest funding round was a Series C round on Apr 14, 2026 for $*****. 17 investors participated in its latest round. Adcendo has 15 institutional investors.

Here is the list of recent funding rounds of Adcendo:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 14, 2026	9656950	Series C	5593409	4541677	4256134	8914931
Nov 25, 2024	8609251	Series B	2701375	3730472	3002999	Logos Capital & 1 more
May 29, 2024	2553890	Series A	9963309	8981451	Dawn Biopharma	Novo Holdings & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Adcendo's funding rounds and investors

The founders of Adcendo are Lars Henning Engelholm and Niels Behrendt. Michael Pehl is the CEO of Adcendo.

Here are the details of Adcendo's key team members:

Lars Henning Engelholm: Co-Founder of Adcendo.
Niels Behrendt: Co-Founder of Adcendo.
Michael Pehl: CEO of Adcendo.

View details of Adcendo's Founder profiles and Board Members

Adcendo's employee count trend

Adcendo has 59 employees as of Mar 26. Here is Adcendo's employee count trend over the years:

Uncover Adcendo's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Adcendo include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of Adcendo, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
9th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
10th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
253rd	Adcendo 2017, Frederiksberg (Denmark), Series C	Developer of antibody-drug conjugates for the treatment of cancer	$323M	Citadel, Logos & 13 others	59/100